close

Enter

Log in using OpenID

Acute Myeloid Leukaemia Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2019 to 2026

embed
The global acute myeloid leukaemia market is poised to value over US$ 1.5 billion by the end of 2026 and registering a CAGR of over 12% during the forecast period, 2019 to 2026
Acute Myeloid Leukaemia Market Global Trends, Market Share, Industry Size,
Growth, Opportunities, and Market Forecast 2019 to 2026
The global acute myeloid leukaemia market is poised to value over US$ 1.5 billion
by the end of 2026 and registering a CAGR of over 12% during the forecast period,
2019 to 2026
Radiation exposure, carcinogenic environmental components, unhealthy lifestyle
and genetic mutations are mainly responsible for acute myeloid leukaemia (AML).
The emergence of alternative AML therapeutics like Tyrosine Kinase Inhibitors,
monoclonal antibodies and multidrug-resistant modulators provides significant
benefits such as improved chances of early detection of cancer cells, improved
quality and safety, reduction in relapse percentage, long term survival rates and so
on.
Some of the major factors impelling the growth of the global acute myeloid
leukaemia market include:
• High mortality rate owing to AML
• Increasing relapse incidences
• The limited response of present medical solutions to treat AML
• Adverse effects of traditional treatments like tissue damage and loss of appetite
in patients
• A rise in the cancer-prone ageing population
• Innovative drug development solutions using molecular biology
• Propelling investments in pharmaceutical R&D by market players
• Research incentives and rapid approvals by government bodies
• Availability of tests that can predict the compatibility of a particular patient with
drug or combination of drugs in achieving positive results
Global Acute Myeloid Leukaemia Market Competitive Scenario
The small and mid-sized pharmaceutical companies are exhibiting prominent
presence with technologically innovative therapeutic techniques providing viable
results. The overall market players pool is competitive with major players like Teva
Pharmaceuticals, Novartis AG and Pfizer. New drug pipelines, extensive clinical trials
and collaborations to proliferate geographic presence would remain major attention
area to gain a competitive advantage in coming years.
Request a Sample Report @ https://www.futurewiseresearch.com/requestsample.aspx?id=177&page=requestsample
Global Acute Myeloid Leukaemia Market Restraints
+ Lack of standardised treatments
+ Mounting preference towards stem cell replacement as an alternative solution
+ Heavily dominated market with the generics
+ High cost of therapeutic treatment processes coupled with safety apprehensions
Global Acute Myeloid Leukaemia Market by Drug Class
+ Tyrosine Kinase Inhibitors
+ Hedgehog Pathway Inhibitors
+ Topoisomerase 2 Inhibitors
+ Others
Tyrosine Kinase Inhibitors have undergone clinical evaluation for identification of
recurring mutations in all phases of drug development, clinical trials (both single
agents plus combination with chemotherapeutics) with promising anti-leukemic
activity outcomes. The biomolecule induces the mobilization of the hematopoietic
progenitors and stem cells in vivo which potentially aid the human biological system
to kill cancer cells. Hence this drug class segment is estimated to dominate the global
AML market over the next couple of years.
Global Acute Myeloid Leukaemia Market by End User
+ Hospital
+ Clinic
+ Others
Global Acute Myeloid Leukaemia Market by Region
+ North America
+ Latin America
+ Europe
+ Asia Pacific
+ Rest of the World
North America leads the global acute myeloid leukaemia market due to existing
patient base and healthcare setups. Besides, it has unique research and development
infrastructure supported by government funds, leading pharmaceutical enterprises
and healthcare organizations. This lead is further followed by the Europe region
which is a hub for medical breakthroughs and skilled healthcare professionals. The
APAC region is estimated to grow at a consistent CAGR in the near future due to
increased awareness about AML, better healthcare infrastructure, rising disposable
income and investment in healthcare innovation.
Purchase a Copy of this Premium Research Report & Ask For Discount:
https://www.futurewiseresearch.com/requestsample.aspx?id=177&page=askfordiscount
Competitive Landscape:
+ Tier 1 players- established companies in the market with a major market share
+ Tier 2 players
+ Emerging players which are growing rapidly
+ New Entrants
FutureWise Key Takeaways
+ Growth prospects
+ SWOT analysis
+ Key trends
+ Key data-points affecting market growth
Objectives of the Study:
+ To provide with an exhaustive analysis on the Global Acute Myeloid Leukaemia
Market by Drug Class, by End User and by Region
+ To cater comprehensive information on factors impacting market growth (drivers,
restraints, opportunities, and industry-specific restraints)
+ To evaluate and forecast micro-markets and the overall market
+ To predict the market size, in key regions (along with countries)—North America,
Europe, Asia Pacific, Latin America, and the Middle East
+ To record evaluate and competitive landscape mapping- product launches,
technological advancements, mergers and expansions
+ Profiling of companies to evaluate their market shares, strategies, financials and
core competencies
Table of Contents
1. Introduction
a. Scope and Objective
b. Assumptions and Acronyms
c. Forecast Factors
d. Research Methodology
2. Executive Summary
a. Industry Cluster Analysis
b. Competition Matrix
c. Strategies Recommendations
3. Market Definition
a. Report Scope (Inclusions & Exclusions)
b. Market Segmentation
4. Global Acute Myeloid Leukemia Market Overview
a. Global Acute Myeloid Leukemia Market Revenue (USD Mn)
5. Key Inclusions
a. Porter’s Five Force analysis
b. Market Dynamics
c. Industry Trends
d. Regulatory Guidelines
e. Opportunities in Acute Myeloid Leukemia
6. Competition Dynamics
a. Company Share Analysis (2018)
b. Top 10 Product Pricing by Region
7. Global Acute Myeloid Leukemia Market Revenue (USD Mn), 2018-2026 by
Drug Class
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Drug Class,
2018-2026
i. Tyrosine Kinase Inhibitors
ii. Hedgehog Pathway Inhibitors
iii. Topoisomerase 2 Inhibitors
iv. Others
8. Global Acute Myeloid Leukemia Market Revenue (USD Mn), 2018-2026 by
End User
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by End User,
2018-2026
i. Hospital
ii. Clinic
iii. Others
9. Global Acute Myeloid Leukemia Market Revenue (USD Mn), 2018-2026 by
Region
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Region,2026
i. North America
ii. Latin America
iii. Europe
iv. Asia Pacific
v. Rest of world
10. North America Acute Myeloid Leukemia Market Revenue (US$ Mn), 20182026
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Country, 20182026
i. US
ii. Canada
e. Market Revenue (USD Mn) Assessment and Forecast by Drug Class,
2018-2026
i. Tyrosine Kinase Inhibitors
ii. Hedgehog Pathway Inhibitors
iii. Topoisomerase 2 Inhibitors
iv. Others
f. Market Revenue (USD Mn) Assessment and Forecast by End User,
2018-2026
i. Hospital
ii. Clinic
iii. Others
11. Latin America Acute Myeloid Leukemia Market Revenue (US$ Mn), 20182026
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Country, 20182026
i. Brazil
ii. Mexico
iii. Argentina
iv. Rest of Latin America
e. Market Revenue (USD Mn) Assessment and Forecast by Drug Class,
2018-2026
i. Tyrosine Kinase Inhibitors
ii. Hedgehog Pathway Inhibitors
iii. Topoisomerase 2 Inhibitors
iv. Others
f. Market Revenue (USD Mn) Assessment and Forecast by End User,
2018-2026
i. Hospital
ii. Clinic
iii. Others
12. Europe America Acute Myeloid Leukemia Market Revenue (US$ Mn), 20182026
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Country, 20182026
i. Germany
ii. France
iii. Spain
iv. UK
v. Russia
vi. Poland
vii. Rest of Europe
e. Market Revenue (USD Mn) Assessment and Forecast by Drug Class,
2018-2026
i. Tyrosine Kinase Inhibitors
ii. Hedgehog Pathway Inhibitors
iii. Topoisomerase 2 Inhibitors
iv. Others
f. Market Revenue (USD Mn) Assessment and Forecast by End User,
2018-2026
i. Hospital
ii. Clinic
iii. Others
13. Asia Pacific America Acute Myeloid Leukemia Market Revenue (US$ Mn),
2018-2026
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Country, 20182026
i. Emerging Asia
1. China
2. India
3. ASEAN-5
4. Rest of Emerging Asia
ii. Japan
e. Market Revenue (USD Mn) Assessment and Forecast by Drug Class,
2018-2026
i. Tyrosine Kinase Inhibitors
ii. Hedgehog Pathway Inhibitors
iii. Topoisomerase 2 Inhibitors
iv. Others
f. Market Revenue (USD Mn) Assessment and Forecast by End User,
2018-2026
i. Hospital
ii. Clinic
iii. Others
14. Rest of World America Acute Myeloid Leukemia Market Revenue (US$ Mn),
2018-2026
a. Key Market Findings
b. Long Term ROI Segments
c. Revenue Opportunity Influencing Factors
d. Market Revenue (USD Mn) Assessment and Forecast by Country, 20182026
i. Middle East
ii. South Africa
iii. North Africa
iv. Rest of World
e. Market Revenue (USD Mn) Assessment and Forecast by Drug Class,
2018-2026
i. Tyrosine Kinase Inhibitors
ii. Hedgehog Pathway Inhibitors
iii. Topoisomerase 2 Inhibitors
iv. Others
f. Market Revenue (USD Mn) Assessment and Forecast by End User,
2018-2026
i. Hospital
ii. Clinic
iii. Others
15. Company Profiles
a. Competition Landscape
b. Global Company Share (USD Mn) Overview, 2018
c. Company Profiles
i. Novartis AG
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
ii. Celgene Corporation
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
iii. Astellas Pharma Inc.
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
iv. Agios Pharmaceuticals, Inc.
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
v. Polaris group
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
vi. Otsuka Pharmaceutical Co., Ltd.
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
vii. Actinium Pharmaceuticals, Inc.
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
viii. Amgen Inc.
1. Corporate Overview
2. Financial Performance
3. Peer Comparison & 3C marketing equation
4. Company Strategy & Channel Management
16. Research Sources & Primary Verbatim
Inquire further details about this report at: [email protected]
About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and
customised solutions for our clients. Through in-depth market insights and
consultancy, we present our clients with the tools they need to be at the forefront
of their industry – a position secured for far more than the near future.
Contact Us:
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Email: [email protected]
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Website: www.futurewiseresearch.com
1/--pages
Report inappropriate content